187 related articles for article (PubMed ID: 9371492)
41. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
42. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Lage H; Helmbach H; Dietel M; Schadendorf D
Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
[TBL] [Abstract][Full Text] [Related]
43. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
Harker WG; Slade DL; Parr RL; Holguin MH
Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
[TBL] [Abstract][Full Text] [Related]
44. Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Morgan SE; Beck WT
Mol Pharmacol; 2001 Feb; 59(2):203-11. PubMed ID: 11160854
[TBL] [Abstract][Full Text] [Related]
45. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.
Chen M; Beck WT
Cancer Res; 1995 Apr; 55(7):1509-16. PubMed ID: 7882360
[TBL] [Abstract][Full Text] [Related]
46. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
Chikamori K; Hill JE; Grabowski DR; Zarkhin E; Grozav AG; Vaziri SA; Wang J; Gudkov AV; Rybicki LR; Bukowski RM; Yen A; Tanimoto M; Ganapathi MK; Ganapathi R
Leukemia; 2006 Oct; 20(10):1809-18. PubMed ID: 16932348
[TBL] [Abstract][Full Text] [Related]
48. Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1.
Allen KA; Williams AO; Isaacs RJ; Stowell KM
Anticancer Drugs; 2004 Apr; 15(4):357-62. PubMed ID: 15057140
[TBL] [Abstract][Full Text] [Related]
49. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Davies SL; Bergh J; Harris AL; Hickson ID
Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
[TBL] [Abstract][Full Text] [Related]
50. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs.
Joshi AA; Wu Z; Reed RF; Suttle DP
Mol Pharmacol; 2003 Feb; 63(2):359-67. PubMed ID: 12527807
[TBL] [Abstract][Full Text] [Related]
51. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
52. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells.
Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD
Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051
[TBL] [Abstract][Full Text] [Related]
53. Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha.
McPherson JP; Goldenberg GJ
Cancer Res; 1998 Oct; 58(20):4519-24. PubMed ID: 9788593
[TBL] [Abstract][Full Text] [Related]
54. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
55. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
56. The effects of 1,4-benzoquinone on c-Myb and topoisomerase II in K-562 cells.
Singh R; Winn LM
Mutat Res; 2008 Oct; 645(1-2):33-8. PubMed ID: 18778717
[TBL] [Abstract][Full Text] [Related]
57. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
Towatari M; Adachi K; Marunouchi T; Saito H
Br J Haematol; 1998 Jun; 101(3):548-51. PubMed ID: 9633900
[TBL] [Abstract][Full Text] [Related]
58. Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIα.
Chen J; Zheng Z; Chen Y; Li J; Qian S; Shi Y; Sun L; Han Y; Zhang S; Yu K
PLoS One; 2016; 11(4):e0153330. PubMed ID: 27058040
[TBL] [Abstract][Full Text] [Related]
59. Regulation of DNA topoisomerase IIalpha stability by the ECV ubiquitin ligase complex.
Yun J; Kim YI; Tomida A; Choi CH
Biochem Biophys Res Commun; 2009 Nov; 389(1):5-9. PubMed ID: 19695223
[TBL] [Abstract][Full Text] [Related]
60. Substrate specificity plays an important role in uncoupling the catalytic and scaffolding activities of rat testis DNA topoisomerase IIalpha.
Bakshi R; Galande S; Muniyappa K
J Biomol Struct Dyn; 2001 Apr; 18(5):749-60. PubMed ID: 11334111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
